MedTrace Logo

Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of Labor

NCT00259103 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2014-05-07

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of rhRlx for cervical ripening, when compared to a placebo.

Conditions

  • Labor, Induced

Interventions

DRUG

Serelaxin

DRUG

Placebo

Sponsors & Collaborators

  • Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies

    lead INDUSTRY

Principal Investigators

  • Sam Teichman, MD · Chief Medical Officer of BAS Medical, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2006-10-31
Completion
2006-10-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00259103 on ClinicalTrials.gov